Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, ...

A type of immunotherapy has shown promising results in targeting the deadliest type of brain cancer, researchers say.

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

Shanghai SinoUnited Hospital today announced the availability of satricabtagene autoleucel ("satri-cel"), the world's first chimeric antigen ...

Cellular immunotherapy uses a patient's own immune cells, including genetically engineered CAR-T, to recognize and destroy cancer cells, and it has emerged as one of the most transformative advances ...

Researchers in London and Canada have found that a new CAR-T cell therapy may eliminate aggressive glioblastoma tumours and ...

Brain cancer is a highly aggressive form of uncontrolled cell growth. What makes brain cancer difficult to treat is its very ...

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly ...